


#### How to change practice in Australasian EDs

Ed Oakley Emergency Physician Royal Children's Hospital Melbourne

#### Bronchiolitis: Burden of disease





#### PREDICT research

# Bronchiolitis Management in Paediatric Emergency Departments in Australia and New Zealand: A PREDICT Study

Babl, Franz E, Sheriff, Nisa, Neutze, Jocelyn, Borland, Meredith, Oakley, Ed.

Pediatric Emergency Care 2008;24(10):656-658 IF:1.1

#### Medication use in infants admitted with bronchiolitis


Oakley E; Brys T; Borland M; Neutze J; Phillips N; Krieser D; Dalziel SR; Davidson A; Donath S; Jachno K; South M; Williams A; Babl FE; Paediatric Research in Emergency Departments International Collaborative (PREDICT). Emergency Medicine Australasia. 30(3):389-397, 2018

#### MedicaPractice variation in acute bronchiolitis

Schuh S, Babl FE, Dalziel S, *etal* Pediatrics. 40(6):, 2017



#### Bronchiolitis: Variation in practice





#### **Bronchiolitis: Variation in practice**




Figure 2. Medication and salbutamol use by age. mo, months. (——), Medication; (— —), salbutamol.



Guidelines are "statements that include <u>recommendations</u> intended to optimize patient care that are informed by a <u>systematic review of evidence</u> and an assessment of the <u>benefits and harms</u> of alternative care options"

Institute of Medicine

#### Bronchiolitis: Local guidance





doi:10.1111/jpc.14104

#### ORIGINAL ARTICLE

#### Australasian bronchiolitis guideline

Sharon O'Brien,<sup>1,2</sup> Meredith L Borland,<sup>1,3</sup> Elizabeth Cotterell,<sup>4</sup> David Armstrong,<sup>5,6</sup> Franz Babl <sup>(0,7,8,9</sup> Paul Bauert,<sup>10</sup> Christine Brabyn,<sup>11</sup> Lydia Garside,<sup>12</sup> Libby Haskell,<sup>13</sup> David Levitt,<sup>14</sup> Nicola McKay,<sup>15</sup> Jocelyn Neutze,<sup>16</sup> Andreas Schibler,<sup>14,17,18</sup> Kam Sinn,<sup>19</sup> Janine Spencer,<sup>20</sup> Helen Stevens,<sup>21</sup> David Thomas,<sup>22</sup> Michael Zhang,<sup>23</sup> Ed Oakley,<sup>8,9,24,25</sup> and Stuart R Dalziel;<sup>13,26,27</sup> on behalf of the Paediatric Research in Emergency Departments International Collaborative (PREDICT) Network, Australasia



#### Bronchiolitis: Local guidance



doi:10.1111/jpc.14104

#### ORIGINAL ARTICLE

#### Australasian bronchiolitis guideline

Sharon O'Brien,<sup>1,2</sup> Meredith L Borland,<sup>1,3</sup> Elizabeth Cotterell,<sup>4</sup> David Armstrong,<sup>5,6</sup> Franz Babl <sup>(0)</sup>,<sup>7,8,9</sup> Paul Bauert,<sup>10</sup> Christine Brabyn,<sup>11</sup> Lydia Garside,<sup>12</sup> Libby Haskell,<sup>13</sup> David Levitt,<sup>14</sup> Nicola McKay,<sup>15</sup> Jocelyn Neutze,<sup>16</sup> Andreas Schibler,<sup>14,17,18</sup> Kam Sinn,<sup>19</sup> Janine Spencer,<sup>20</sup> Helen Stevens,<sup>21</sup> David Thomas,<sup>22</sup> Michael Zhang,<sup>23</sup> Ed Oakley,<sup>8,9,24,25</sup> and Stuart R Dalziel;<sup>13,26,27</sup> on behalf of the Paediatric Research in Emergency Departments International Collaborative (PREDICT) Network, Australasia

Do not use beta-2 agonists (GRADE strong)

**Do not use** adrenaline (GRADE strong)

Do not use glucocorticoids (GRADE strong)

**Do not use** antibiotics (GRADE conditional)

Routine CXR not recommended (GRADE conditional)



#### Bronchiolitis: Local guidance





**NICE** National Institute for Health and Care Excellence



#### Bronchiolitis: Knowledge translation

What is known

# What is currently done

#### Bronchiolitis: Knowledge translation

Haskell et al. BMC Pediatrics (2018) 18:218 https://doi.org/10.1186/s12887-018-1187-7

#### **BMC** Pediatrics

#### STUDY PROTOCOL

#### **Open Access**



Implementing evidence-based practices in the care of infants with bronchiolitis in Australasian acute care settings: study protocol for a cluster randomised controlled study

Libby Haskell<sup>1,2\*</sup>, Emma J. Tavender<sup>3,4</sup>, Catherine Wilson<sup>3</sup>, Sharon O'Brien<sup>5</sup>, Franz E. Babl<sup>3,6,7</sup>, Meredith L. Borland<sup>5,8</sup>, Liz Cotterell<sup>9,10</sup>, Tibor Schuster<sup>3,11</sup>, Francesca Orsini<sup>3,11</sup>, Nicolette Sheridan<sup>12</sup>, David Johnson<sup>13</sup>, Ed Oakley<sup>3,6,7</sup>, Stuart R. Dalziel<sup>1,2</sup> on behalf of PREDICT<sup>14</sup>

### KT bronchiolitis study

Haskell et al. BMC Pediatrics (2018) 18:218 https://doi.org/10.1186/s12887-018-1187-7

**BMC** Pediatrics

#### STUDY PROTOCOL



Implementing evidence-based practices in the care of infants with bronchiolitis in Australasian acute care settings: study protocol for a cluster randomised controlled study

Libby Haskell<sup>1,2\*</sup>, Emma J. Tavender<sup>3,4</sup>, Catherine Wilson<sup>3</sup>, Sharon O'Brien<sup>5</sup>, Franz E. Babl<sup>3,6,7</sup>, Meredith L. Borland<sup>5,8</sup>, Liz Cotterell<sup>9,10</sup>, Tibor Schuster<sup>3,11</sup>, Francesca Orsini<sup>3,11</sup>, Nicolette Sheridan<sup>12</sup>, David Johnson<sup>13</sup>, Ed Oakley<sup>3,6,7</sup>, Stuart R. Dalziel<sup>1,2</sup> on behalf of PREDICT<sup>14</sup>

#### To determine whether

Aim

#### tailored, theory informed KT intervention

VS.

#### passive guideline dissemination

improves compliance with the Australian Bronchiolitis Guideline (CXR, antibiotics, adrenaline, glucocorticoids and salbutamol)

Paediatric Research in Emergency Departments International Collaborative

# KT bronchiolitis study

**Methods** 

Multi-centered cluster RCT

Haskell et al. BMC Pediatrics (2018) 18:218 https://doi.org/10.1186/s12887-018-1187-7

**BMC** Pediatrics

#### STUDY PROTOCOL



Implementing evidence-based practices in the care of infants with bronchiolitis in Australasian acute care settings: study protocol for a cluster randomised controlled study

Libby Haskell<sup>1,2\*</sup>, Emma J. Tavender<sup>3,4</sup>, Catherine Wilson<sup>3</sup>, Sharon O'Brien<sup>5</sup>, Franz E. Babl<sup>3,6,7</sup>, Meredith L. Borland<sup>5,8</sup>, Liz Cotterell<sup>9,10</sup>, Tibor Schuster<sup>3,11</sup>, Francesca Orsini<sup>3,11</sup>, Nicolette Sheridan<sup>12</sup>, David Johnson<sup>13</sup>, Ed Oakley<sup>3,6,7</sup>, Stuart R. Dalziel<sup>1,2</sup> on behalf of PREDICT<sup>14</sup>

- Comparing a tailored, theory informed KT intervention to passive dissemination of a bronchiolitis guideline
- KT interventions designed following qualitative interviews using the Theoretical Domains Framework to identify key factors influencing bronchiolitis management



# KT bronchiolitis study

#### Site inclusion

- ED census >135 cases per year
- Be willing to participate in control or intervention
- Signed consent by ED and pediatric inpatient clinical directors
- Ability to audit clinical notes
- Nominate a clinical lead for duration of study

#### Site exclusion

- Inability to audit clinical notes
- Be averse to participating if randomised to control



#### KT bronchiolitis study - Primary outcome

# Compliance or non-compliance during the first 24hrs following presentation to ED



PREDICT Paediatric Research in Emergency Departments International Collaborative

# KT bronchiolitis study – Secondary outcomes

- Compliance or non-compliance for each key therapy
  - While in ED
  - While an inpatient
  - During acute care period (first 24hours)
  - During total hospitalization
- Length of stay
- Death or ICU admissions



# KT bronchiolitis study – Data extraction

- Retrospective
- Randomized cases (n=100-150/year)
  - <1 year old</pre>
  - ED and final diagnosis bronchiolitis
- Intervention year (2017) + 2 years prior



• Statistics: 90% power to show an absolute difference of 15%




### KT bronchiolitis study - Sites





20






# KT bronchiolitis study – Interventions

✓	~
	$\checkmark$
	$\checkmark$
$\checkmark$	$\checkmark$
✓	
	• •
	•


Emergency Departments International Collaborative

#### KT bronchiolitis study – Study flow





### KT bronchiolitis study – Study flow



#### KT bronchiolitis study – Baseline

	Control n = 1,810	Intervention n = 1,917			
Characteristics of infants included in study during intervention year					
Age - mean +/- SD, months	6.0 (SD 3.14)	5.9 (SD 3.18)			
<b>Female</b> - no. (%)	666 (37%)	733 (38%)			
Race or ethnic group – no. (%)					
Aboriginal/Torres Strait Islander (Australia)	169 (9%)	126 (7%)			
Maori/Pacific Islander (New Zealand)	248 (14%)	269 (14%)			
Other	1,393 (77%)	1,519 (79%)			
Past medical history					
Premature birth – no. (%)	281 (16%)	224 (12%)			
Hx of co-morbidities - no. (%)	90 (5%)	82 (4%)			

#### KT bronchiolitis study – Baseline

	Control n = 1,810	Intervention n = 1,917			
Characteristics of infants included in study during intervention year					
Age - mean +/- SD, months	6.0 (SD 3.14)	5.9 (SD 3.18)			
<b>Female</b> - no. (%)	666 (37%)	733 (38%)			
Race or ethnic group – no. (%)					
Aboriginal/Torres Strait Islander (Australia)	169 (9%)	126 (7%)			
Maori/Pacific Islander (New Zealand)	248 (14%)	269 (14%)			
Other	1,393 (77%)	1,519 (79%)			
Past medical history					
Premature birth – no. (%)	281 (16%)	224 (12%)			
Hx of co-morbidities - no. (%)	90 (5%)	82 (4%)			

### KT bronchiolitis study – Primary outcome

	Control (n=1,810)	Intervention (n=1,917)	Risk difference (95%Cl)	P value
Compliance during first 24 hours with regard to chest x-ray, salbutamol, glucocorticoids, antibiotics and epinephrine	1,321 (73%)	1,631 (85%)	12.1% (6.5%-21.7%)	<0.001



## KT bronchiolitis study – Primary outcome

	Control (n=1,810)	Intervention (n=1,917)	Risk difference (95% <del>Cl)</del>	P value	
Compliance in ED	1,427 (79%)	1,671 (87%)	8.8% (4.1%- 17.4%)	0.002	
Compliance as inpatient	1,499 (83%)	1,735 (91%)	8.5% (2.7%- 14.3%)	0.004	
Compliance during total hospitalisation	1,265 (70%)	1,576 (82%)	12.4% (6.2%- 22.6%)	<0.001	liatric Research in

# KT bronchiolitis study – Secondary outcomes

Compliance for each patient presentation during the first 24 hours following presentation to ED with regard to:	Control (n=1,810)	Intervention (n=1,917)	Risk difference (95%Cl)	P value
Chest x-ray (for a respiratory cause)	1,635 (90%)	1,786 (93%)	4.0% (0.6%-8.6%)	0.05
Salbutamol	1,598 (88%)	1,825 (95%)	7.8% (4.5%-11.0%)	<0.001
Glucocorticoids	1,777 (98%)	1,891 (99%)	3.0% (0.7%-1.2%)	0.56
Antibiotics (for a respiratory cause)	1,772 (98%)	1,873 (98%)	0.5% (-1.2%-2.3%)	0.56
Epinephrine	1,807 (99%)	1,915 (99%)	0.1% (-0.2%-0.4%)	0.53

#### KT bronchiolitis study – Secondary outcomes

	Control (n=1,810)	Intervention (n=1,917)	IRR/RD (95%CI)	P value
Length of stay (hours) – median (IQR)	11 (2, 45)	12 (2, 42)	IRR 0.94 (0.7%-1.24%)	0.67
Death/ICU admission – n (%)	41 (2%)	63 (3%)	RD 0.38 (-0.22-0.99)	0.21

### KT bronchiolitis study – Limitations

- Not possible to blind staff
- Data collected retrospectively
  - However needed to do this to avoid Hawthorne effect
- Participants needed both an ED and discharge diagnosis of bronchiolitis
  - Therefore true compliance will be lower than reported
- Smaller hospitals excluded
- Sustainability



### Guidelines

- Compliance improved from 61% to 73% just with
  - Guideline
  - Local dissemination
  - Consistent wider international message

- Compliance improved to 85% with
  - Tailored KT intervention



# Conclusion

- High quality Guidelines can improve care
- Good KT will maximise reward
- But effort should be worth potential benefit